Azalea Vision BV

Azalea Vision BV is a pioneering company in ocular technology, focusing on innovative vision enhancement solutions that integrate advanced sensing and monitoring capabilities with a premium user experience. Founded in 2021 in Zwijnaarde, Belgium, Azalea Vision BV specializes in ocular technology, offering Smart Adaptive Vision lenses that enhance vision while monitoring ocular health. The company has completed 3 deals as of April 29, 2025, when it raised EUR 9 million in Series A funding from SPRIM Global Investments and Afrimobility, the total amount raised since inception being EUR 9 million. Azalea Vision specializes in advanced ocular technology designed to revolutionize eye care and vision enhancement.

Their core offering, the Smart Adaptive Vision lenses, integrates real-time sensing, microelectronics, and NFC capabilities to go beyond traditional vision correction. These lenses provide visual clarity and the ability to monitor ocular health by detecting biomarkers for conditions like glaucoma and diabetes. The product enables seamless interaction with external devices, allowing users to control lens functionalities through simple gestures. Azalea Vision targets healthcare providers, eye care professionals, and end consumers globally, seeking innovative solutions for personalized eye care.

Azalea Vision's revenue model is primarily based on direct-to-consumer sales and partnerships with healthcare providers and optical retailers. The company generates revenue through individual sales of its Smart Adaptive Vision lenses and potentially subscription services for ongoing monitoring and support. Transactions typically involve direct sales to consumers as well as distribution through specialized eye care clinics and retailers, ensuring accessibility across various regions. Pricing plans reflect the advanced features and capabilities of the lenses, positioning them as a premium product in the ocular health market.

In April 2025, Azalea Vision BV raised EUR 9 million in Series A funding to conduct its First-in-Human pilot clinical trial, pursue FDA Investigational Device Exemption approval, and advance commercialization of its ocular technology platform. The company is also designing new products aimed at enhancing user experience and aims to enter new markets, targeting specific regions by late 2025. Recent funding will support these initiatives, ensuring the advancement of their innovative technology.